Comparative Pharmacology
Head-to-head clinical analysis: HYDRODIURIL versus INDERIDE LA 80 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRODIURIL versus INDERIDE LA 80 50.
HYDRODIURIL vs INDERIDE LA 80/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
Combination of propranolol (non-selective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
One capsule orally once daily, containing propranolol hydrochloride 80 mg (immediate release) and hydrochlorothiazide 50 mg. May be titrated based on response, with maximum propranolol dose 640 mg/day and maximum hydrochlorothiazide dose 50 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Propranolol: 3-6 hours (poor metabolizers up to 10 hours). Hydrochlorthiazide: 6-15 hours (prolonged in renal impairment).
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal elimination of propranolol and hydrochlorthiazide: propranolol is extensively metabolized in the liver, <1% excreted unchanged in urine; hydrochlorthiazide is excreted unchanged in urine (≥95% renal).
Category C
Category C
Thiazide Diuretic
Beta Blocker and Thiazide Diuretic